GERN

Geron is a single-product commercial-stage biotech whose entire equity story rests on RYTELO (imetelstat), FDA-approved in June 2024 for lower-risk MDS with TD anemia and EC-approved in March 2025 for the EU. The MD&A confirms management is leaning into the launch — partnering with Tanner Pharma for ex-US Named Patient Programs and preparing select EU launches in 2026 via third parties rather than building its own commercial infrastructure abroad. That capital-light international approach is sensible for a company that has 'not reported any profit since 2015' and finances itself through equity and debt.

The numbers tell a mixed story. FY2025 net loss narrowed sharply to -$83.5M from -$175M (+52.2% YoY), operating loss improved +60.5%, and operating cash burn improved to -$111M from roughly -$218M — strong directional progress consistent with RYTELO revenue ramping. However, the FY2024 and FY2025 revenue lines in the provided data are blank, which makes the headline P/S of 3,932x (computed against stale FY2023 revenue of $237K) meaningless. Management states they had ~$401M in cash, equivalents, restricted cash and marketable securities at YE2025, well above the $77.6M cash-only line — that liquidity, plus $120M long-term Pharmakon debt that restricts dividends, frames a runway question that the provided data cannot fully answer.